kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - other antineoplastic agents - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse.• adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy.• adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
kymriah
novartis israel ltd - tisagenlecleucel - dispersion for infusion - tisagenlecleucel - kymriah is indicated for the treatment of: - paediatric and young adult patients up to and including 25 years of age with cd19+ b-cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post-transplant or in second or later relapse. - adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy. limitation of use: kymriah is not indicated for treatment of patients with primary or secondary central nervous system lymphoma- adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy
echinaforce throat spray
a.vogel uk ltd - sage leaf; echinacea root extract; echinacea - spray - 430mg/1ml ; 45.5mg/1ml ; 863.3mg/1ml
hlgeen harrar massage cream
household & toiletries manufacturing co. ltd (htm), jordan - massage cream -
msl medical massage bed
medicare surgical , tanzania - massage bed -
full body physio massage gum therapy model no ped 203
curett health solutions pvt ltd, tanzania - massage apparatus -
kymriah suspension
novartis pharmaceuticals canada inc - tisagenlecleucel - suspension - 600000000cells - tisagenlecleucel 600000000cells - antineoplastic agents
cellular therapies
novartis pharmaceuticals australia pty ltd - tisagenlecleucel, quantity: 1200000 cells - suspension - excipient ingredients: glucose; sodium; chloride; albumin; aluminium; magnesium; dimethyl sulfoxide; gluconic acid; acetate; caprylate; furfural; dimethyl sulfone; dextran 40; potassium; n-acetyltryptophan - cellular therapies - kymriah is a genetically modified autologous immunocellular therapy indicated for the treatment of paediatric and young adult patients up to 25 years of age with b-cell precursor acute lymphoblastic leukaemia (all) that is refractory, in relapse post-transplant, or in second or later relapse.
cellular therapies
novartis pharmaceuticals australia pty ltd - tisagenlecleucel, quantity: 60000000 cells - suspension - excipient ingredients: n-acetyltryptophan; albumin; acetate; gluconic acid; sodium; magnesium; potassium; dimethyl sulfoxide; glucose; aluminium; caprylate; dextran 40; furfural; dimethyl sulfone; chloride - cellular therapies - kymriah is a genetically modified autologous immunocellular therapy indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy. kymriah is not indicated for patients with primary central nervous system lymphoma.
propolis capsule 2000mg
homart pharmaceuticals pty ltd - propolis, quantity: 2 g (equivalent: propolis dry extract, qty 400 mg; equivalent: lead, qty 4 microgram) - capsule, soft - excipient ingredients: purified water; soya oil; white beeswax; lecithin; glycerol; hydrogenated vegetable oil; iron oxide black; gelatin; d-alpha-tocopherol; carob pod; iron oxide red; grape seed oil; yellow beeswax - antioxidant/reduce free radicals formed in the body ; maintain/support general health and wellbeing ; traditionally used in western herbal medicine to maintain/support immune system health ; traditionally used in western herbal medicine to maintain/support healthy immune system function